News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

David Bearss Resigns as Chief Scientific Officer to Join Huntsman Cancer Institute as Co-director of Center for Investigational Therapeutics


9/21/2009 9:41:14 AM

DUBLIN, Calif.--(BUSINESS WIRE)--SuperGen Inc. (Nasdaq:SUPG) announced that, effective October 16, 2009, David Bearss, Ph.D., will resign as SuperGen’s Chief Scientific Officer, and be engaged as a long-term biology consultant to the Company. In addition, Dr. Bearss will retain his Scientific Advisory Board membership at SuperGen. Dr. Bearss will return to academic cancer research, as Co-director of the Center for Investigational Therapeutics of Huntsman Cancer Institute at the University of Utah.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES